Related Experiment Video
Updated: Jun 13, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2
Manshan Xu1, Shilpa Choudhary, Olga Voznesensky
1Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA.
Abstract:
Cyclooxygenase-2 (COX-2) knockout (KO) mice in inbred strains can have renal dysfunction with secondary hyperparathyroidism (HPTH), making direct effects of COX-2 KO on bone difficult to assess. COX-2 KO mice in an outbred CD-1 background did not have renal dysfunction but still had two-fold elevated PTH compared to wild type (WT) mice. Compared to WT mice, KO mice had increased serum markers of bone turnover, decreased femoral bone mineral density (BMD) and cortical bone thickness, but no differences in trabecular bone volume by microCT or dynamic histomorphometry. Because PTH is a potent inducer of COX-2 and prostaglandin (PG) production, we examined the effects of COX-2 KO on bone responses after 3 weeks of intermittent PTH. Intermittent PTH increased femoral BMD and cortical bone area more in KO mice than in WT mice and increased trabecular bone volume in the distal femur in both WT and KO mice. Although not statistically significant, PTH-stimulated increases in trabecular bone tended to be greater in KO mice than in WT mice. PTH increased serum markers of bone formation and resorption more in KO than in WT mice but increased the ratio of osteoblastic surface-to-osteoclastic surface only in KO mice. PTH also increased femoral mineral apposition rates and bone formation rates in KO mice more than in WT mice. Acute mRNA responses to PTH of genes that might mediate some anabolic and catabolic effects of PTH tended to be greater in KO than WT mice. We conclude that (1) the basal bone phenotype in male COX-2 KO mice might reflect HPTH, COX-2 deficiency or both, and (2) increased responses to intermittent PTH in COX-2 KO mice, despite the presence of chronic HPTH, suggest that absence of COX-2 increased sensitivity to PTH. It is possible that manipulation of endogenous PGs could have important clinical implications for anabolic therapy with PTH.
Insights
Cyclooxygenase-2 (COX-2) knockout mice show altered bone turnover and reduced bone density. However, these mice exhibit enhanced responses to parathyroid hormone (PTH) therapy, suggesting potential for improved bone anabolic treatments.
Area of Science:
- Bone biology and endocrinology
- Pharmacology and drug discovery
Background:
- Cyclooxygenase-2 (COX-2) knockout (KO) mice can exhibit renal dysfunction and secondary hyperparathyroidism (HPTH), complicating bone studies.
- COX-2 KO mice on a CD-1 background lack renal dysfunction but show elevated parathyroid hormone (PTH) levels.
Purpose of the Study:
- To investigate the effects of COX-2 deficiency on bone metabolism and response to parathyroid hormone (PTH) therapy.
- To determine if COX-2 deficiency influences bone's sensitivity to PTH, a key regulator of bone turnover.
Main Methods:
- Comparison of bone parameters (BMD, cortical thickness, trabecular volume) between COX-2 KO and wild-type (WT) mice.
- Assessment of bone responses to 3 weeks of intermittent PTH administration in both KO and WT mice.
- Analysis of bone turnover markers, histomorphometry, and gene expression related to PTH signaling.
Main Results:
- COX-2 KO mice displayed increased bone turnover markers, decreased femoral BMD, and reduced cortical thickness compared to WT mice.
- Intermittent PTH administration led to greater increases in femoral BMD and cortical bone area in KO mice versus WT mice.
- PTH-stimulated bone formation and resorption markers, as well as mineral apposition rates, were higher in KO mice, indicating increased sensitivity to PTH.
Conclusions:
- The basal bone phenotype in male COX-2 KO mice may be attributed to HPTH, COX-2 deficiency, or a combination of both.
- Absence of COX-2 enhances bone sensitivity to intermittent PTH, suggesting that modulating endogenous prostaglandins could be a viable strategy for PTH-based anabolic bone therapy.
More Related Videos
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Remodeling
Osteoclasts in Bone Remodeling
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
Skeleton and Calcium Homeostasis
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

